Shot vs. IV: could a simple injection improve stomach cancer treatment?
NCT ID NCT07449780
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two ways of giving the immunotherapy drug AK104 alongside standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. One group gets AK104 as a shot under the skin (subcutaneous), the other as an IV infusion. The goal is to see if the shot works as well and is safer. About 422 participants will take part, and the study has not started recruiting yet.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK104 (a type of immunotherapy) plus oxaliplatin and capecitabine chemotherapy
What this could lead to
If successful, this could offer a more convenient subcutaneous injection option for immunotherapy in advanced gastric cancer, potentially improving quality of life.
What could go wrong
This is an early-stage comparison of two delivery methods; it may not show a clear benefit in survival or tumor shrinkage. Side effects from immunotherapy and chemotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••